Related Posts
- Cardiovascular toxicities associated with bispecific T-cell engager therapy
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials…
- 1432 Cancer-associated fibroblasts metabolic targeting overcomes T-cell exclusion and chemoresistance
Background Recent advances in T cell-based immunotherapies have shown promise in controlling tumor growth, but…
- 1184 A platform for tuning therapeutic efficacy of T-Cell-engaging bispecific antibodies
Background T-cell activation requires appropriate strength of stimulation and costimulation. Blocking coinhibitory pathways prevents T-cell…